LOS ANGELES: BPN14770 is a novel therapeutic agent that works through the PKA-CREB pathway to enhance synaptic action of the brain neurons involved in memory and cognition. This unique mechanism of action has the potential to improve cognitive and memory function in devastating disorders including Alzheimer’s disease, schizophrenia, and learning/developmental disabilities such as Fragile X syndrome. Tetra plans to evaluate the therapeutic potential of BPN14770 in reversing memory dysfunction as well as its ability to slow the progression of Alzheimer’s disease.
In the Multiple Ascending Dose trial (MAD), Tetra will study both young and elderly healthy volunteers who will receive daily doses of BPN14770. The subjects will be housed in a clinic setting and carefully monitored to detect any potential effects of the drug. In addition, elderly subjects will receive tests of their memory and cognitive ability throughout the dosing period. Particular attention will be paid to improvements in long-term memory, the key potential benefit of BPN14770. This study will pave the way for Phase 2 studies in patients with cognitive disorders including Alzheimer’s disease.
“We are hopeful that treatment with BPN14770 will lead to improved memory and cognition in individuals with non-amyloid or amyloid-related forms of dementia,” said Scott Reines, M.D., Ph.D., chief medical officer of Tetra.